We have previously shown that the toxic
pro-oxidant methylselenol is released from
selenomethionine (SeMET) by
cancer cells transformed with the adenoviral
methionine alpha,gamma-
lyase (
methioninase, MET) gene cloned from Pseudomonas putida.
Methylselenol damaged the mitochondria via oxidative stress, and caused
cytochrome c release into the cytosol thereby activating
caspase enzymes and thereby apoptosis. However, gene therapy strategies are less effective if
tumor cells overexpress the antiapoptotic
mitochondrial protein bcl-2. In this study, we investigated whether rAdMET/SeMET was effective against bcl-2-overproducing A549
lung cancer cells. We established two clones of the human
lung cancer A549 cell line that show moderate and high expression levels of bcl-2, respectively, compared to the parent cell line, which has very low bcl-2 expression.
Staurosporine-induced apoptosis was inhibited in the bcl-2-overproducing clones as well as in the parental cell line. In contrast to
staurosporine, apoptosis was induced in the bcl-2-overproducing clones as well as the parental cell line by AdMET/SeMET. Apoptosis in the rAdMET-SeMET-treated cells was determined by fragmentation of nuclei, and release of
cytochrome c from mitochondria to the cytosol. A strong bystander effect of AdMET/SeMET was observed on A549 cells as well as the bcl-2-overproducing clones. rAdMET/SeMET
prodrug gene therapy is therefore a promising novel strategy effective against bcl-2 overexpression, which has blocked other gene therapy strategies.